Background and aim : Diabetes is a major cause of chronic kidney disease (CKD). Urine albumin and estimated glomerular filtration rate (eGFR) are the two key markers for chronic kidney disease (CKD). The aim of our work was to explore the possibility of plasma cystatin C and urinary sE.cadherin as useful biomarkers for early detection of diabetic nephropathy (DN). Methods:-A total number of 80 subjects were included and were classified into three main groups. Group I (20) normal subjects with no history of DM, hypertension or other diseases and with albumin / creatinine (Alb / Cr) ratio below 30 mg/ g. Group II (30) type 2 diabetic patients with Alb / Cr ratio below 30 mg/ g. Group III (30) type 2 diabetic patients with Alb / Cr ratio between 30 and 300 mg/ g. The latter two groups were divided in two sub groups A and B according to GFR by MDRD: normal (≥ 90 ml /min / 1.73 m2) and < 90 ml /min / 1.73 m2. All subjects underwent urine analysis, complete blood picture, liver function tests, kidney function tests, INR, fasting plasma glucose level, HbA1c, lipid profile, abumin/creatinine ratio, pelvi-abdominal ultrasound, plasma Cystatin C and urinary human sE-Cadherin. Results:-Plasma cystatin C and urinary sE.cadherin/ cr levels were increased with micro-albuminuria. Also, plasma cystatin C and urinary sE.cadherin/ cr levels were significant between normoalbuminuric subjects with GFR ≥ 90 mL/min/1.73 m2 calculated by the MDRD equation and those below 90 mL/min/1.73 m2 being higher in the later. In multivariate logistic analysis, plasma cystatin C level was the only independent factor associated with eGFR < 90 mL/min/1.73m2 estimated by MDRD equation in patients with normoalbuminuria. There are high significant positive correlations of plasma cystatin C with age, total cholesterol unlike urinary sE.cadherin/ cr, but both had positive correlations with serum Cr, blood urea and Alb / Cr ratio and negative correlations with GFR. Conclusion and Recommendations:-Plasma cystatin C and urinary sE.cadherin levels could be useful markers for detection of microalbuminuria and renal impairment in type 2 diabetic patients with normoalbuminuria.
Background: To assess the validity of measuring plasma Angiopoietin as a biomarker for early detection of diabetic nephropathy and todetermine the relation between plasma Ang-2 and inflammation in diabetic nephropathy patients in Zagazig university Hospitals. Subjects and methods:This study included a total of 76 diabetic patients divided to microalbuminuria and macroalbuminuria groups , each group contained 38 patients in addition to 40 healthy control subjects. Results: Plasma levels of Ang-2 was significantly higher in patients with microalbuminuria and macroalbuminuria compared to healthy controls. Indeed, Ang-2 levels steadily increases with the progression of albuminuria. The study showed significant positive correlation between plasma Ang-2 , MAP and creatinine, uric acid, phosphorus, CRP, total cholesterol and triglycrides. We observed also significant negative correlation between plasma Ang-2 and Hb, eGFR, serum calcium and albumin. Conclusion:Our results indicated that Plasma Angiopoietin-2 levels are elevated in patients with diabetic nephropathy. plasma Ang-2 steadily increase with the progression of albuminuria, suggesting their possible role as early markers of microvascular angiopathy of glomeruli. Plasma Ang-2 is related to CRP, this implies that elevated levels of this biomarker occur as a result of inflammation and vascular dysfunction as a part of atherosclerotic process. Abbreviations: Ang-2 =Angiopoietin-2, CRP = C-reactive protein, Hb= hemoglobin, ACR = albumin-creatinine ratio, ESRD = end stage renal disease, MAP= mean arterial pressure, FBS = fasting blood suger.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.